Uncategorized
Speaker describes nanostructured sustained-release drug delivery system
BOSTON — A new device in development for the sustained release of ocular therapies is nanostructured to optimize drug delivery, is completely bioerodible and can be administered intraocularly intramuscularly or subcutaneously, a speaker here said. Focusing on long-term sustained delivery, the delivery system, called Tethadur, is designed for the release of large molecules, including antibodies to the eye, according to Paul Ashton, president and CEO of pSivida.